Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment
Standard
Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment. / Möckelmann, Nikolaus; Kriegs, Malte; Lörincz, Balazs B; Busch, Chia-Jung; Knecht, Rainald.
in: HEAD NECK-J SCI SPEC, Jahrgang 38, Nr. Suppl 1, 04.2016, S. E2173-81.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment
AU - Möckelmann, Nikolaus
AU - Kriegs, Malte
AU - Lörincz, Balazs B
AU - Busch, Chia-Jung
AU - Knecht, Rainald
N1 - © 2015 Wiley Periodicals, Inc.
PY - 2016/4
Y1 - 2016/4
N2 - BACKGROUND: Significant evidence exists supporting the use of platinum-based chemoradiation (CRT) as a primary curative approach in locoregionally advanced head and neck cancer (LA-HNSCC). Despite these aggressive protocols, 70% of patients die within five years due to locoregional recurrence or distant metastasis. To increase the response and survival of HNSCC patients, CRT has been combined with molecular agents targeting distinct kinases.METHODS: This study was performed using a systematic literature review.RESULTS: The effect of targeted therapy on patient survival in the context of CRT remains controversial, with toxicities tending to be more severe but still acceptable.CONCLUSIONS: Supplementing CRT with target therapeutics might only improve survival in some LA-HNSCC patients. Therefore, future studies must address the underlying biological mechanisms which can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of LA-HNSCC patients by combining CRT and targeted therapy. This article is protected by copyright. All rights reserved.
AB - BACKGROUND: Significant evidence exists supporting the use of platinum-based chemoradiation (CRT) as a primary curative approach in locoregionally advanced head and neck cancer (LA-HNSCC). Despite these aggressive protocols, 70% of patients die within five years due to locoregional recurrence or distant metastasis. To increase the response and survival of HNSCC patients, CRT has been combined with molecular agents targeting distinct kinases.METHODS: This study was performed using a systematic literature review.RESULTS: The effect of targeted therapy on patient survival in the context of CRT remains controversial, with toxicities tending to be more severe but still acceptable.CONCLUSIONS: Supplementing CRT with target therapeutics might only improve survival in some LA-HNSCC patients. Therefore, future studies must address the underlying biological mechanisms which can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of LA-HNSCC patients by combining CRT and targeted therapy. This article is protected by copyright. All rights reserved.
U2 - 10.1002/hed.24031
DO - 10.1002/hed.24031
M3 - SCORING: Journal article
C2 - 25783524
VL - 38
SP - E2173-81
JO - HEAD NECK-J SCI SPEC
JF - HEAD NECK-J SCI SPEC
SN - 1043-3074
IS - Suppl 1
ER -